WW International(NASDAQ: WW) was going through quite a slimdown this week, at least as far as its stock was concerned.
Investors traded out of the WeightWatchers parent company following a downbeat note from a researcher, and the introduction of a competing product from a top healthcare company. According to data compiled by S&P Global Market Intelligence, the stock had lost over 22% of its value week to date as of early Friday morning.
Barclays says WW International is a sell
The new year didn't start off well for WW International. On Tuesday, the first trading day of 2024, Barclays initiated coverage on the stock with an underweight (read: sell) recommendation at a price target of $8 per share.
That was a prescient call, as only two days later healthcare giant Eli Lilly launched a new e-commerce platform called LillyDirect. The company didn't hesitate to mention that LillyDirect specifically targets customers "living with obesity, migraine, and diabetes."
That was hardly an accident, as the rollout comes shortly after Lilly began marketing Zepbound, its weight loss drug that competes with Novo Nordisk's massively popular Wegovy. By extension, it also competes with the classic weight-shedding routines and diets that form the core of WW International's business.
Investors might have overreacted
Neither development is positive. However, a 22% sell-off feels drastic. WW International still operates the well-known and therefore powerful WeightWatchers brand, and has a wide user base. While the Eli Lilly platform will doubtless offer significant competition, WW International had advantages it can leverage in the fight.
Should you invest $1,000 in WW International right now?
Before you buy stock in WW International, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now... and WW International wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Stock Advisor provides investors with an easy-to-follow blueprint for success, including guidance on building a portfolio, regular updates from analysts, and two new stock picks each month. The Stock Advisor service has more than tripled the return of S&P 500 since 2002*.
*Stock Advisor returns as of December 18, 2023
Eric Volkman has no position in any of the stocks mentioned. The Motley Fool recommends Barclays Plc and Novo Nordisk. The Motley Fool has a disclosure policy.
